Xponance Inc. Makes New $242,000 Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Xponance Inc. bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,978 shares of the company’s stock, valued at approximately $242,000.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Hims & Hers Health by 9.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock worth $19,117,000 after buying an additional 193,507 shares during the period. Farallon Capital Management LLC grew its holdings in shares of Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares during the last quarter. Finally, Verition Fund Management LLC increased its position in Hims & Hers Health by 30.9% in the 4th quarter. Verition Fund Management LLC now owns 798,660 shares of the company’s stock valued at $7,108,000 after acquiring an additional 188,506 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Oluyemi Okupe sold 12,651 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $16.79, for a total value of $212,410.29. Following the sale, the chief financial officer now directly owns 211,000 shares in the company, valued at $3,542,690. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $16.47, for a total value of $3,110,985.36. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $551,777.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 12,651 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $16.79, for a total value of $212,410.29. Following the sale, the chief financial officer now owns 211,000 shares in the company, valued at approximately $3,542,690. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 542,585 shares of company stock valued at $8,751,851. Corporate insiders own 17.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on HIMS shares. Piper Sandler reaffirmed a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Jefferies Financial Group lifted their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, June 27th. Bank of America cut their price objective on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, September 13th. Needham & Company LLC began coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Finally, TD Cowen increased their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.86.

Hims & Hers Health Stock Down 2.0 %

Hims & Hers Health stock opened at $18.93 on Thursday. The firm has a market capitalization of $4.07 billion, a PE ratio of -1,893.00 and a beta of 1.05. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74. The firm’s 50-day simple moving average is $16.75 and its 200 day simple moving average is $17.26.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. The company’s revenue for the quarter was up 51.8% compared to the same quarter last year. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.